SetPoint intends to offer patients and providers a better alternative for the treatment of chronic inflammatory diseases with less risk and lower cost than drug therapy. SetPoint believes neuromodulation for the treatment of rheumatoid arthritis and other inflammatory diseases will be ground-breaking for patients, physicians and payors:

The SetPoint Platform

  • For patients, the implanted microregulator is intended to last 10 years, freeing them from routine injections or pills and the risks and substantial cost associated with current treatments.


  • For physicians, the device is designed to provide a novel and less expensive alternative for patients suffering from RA.


  • For payors, the device may improve the lives of those suffering from RA, while decreasing costs by up to 75%.


CAUTION: Investigational device in the US and the European Union. Limited by country law to investigational use only.

SetPoint Medical is dedicated to treating patients with debilitating inflammatory diseases, such as Crohn's Disease and rheumatoid arthritis, using proprietary implantable neuromodulation devices.

The scientific platform is based on the Inflammatory Reflex—the natural mechanism by which the central nervous system regulates the immune system. This mechanism was discovered by SetPoint co-founder Kevin Tracey and published in Nature in May 2000. Since then, the Inflammatory Reflex has been characterized in more than 100 peer reviewed papers in leading scientific journals. Anti-inflammatory potency comparable to leading drugs has been demonstrated in multiple animal models. The company is currently conducting human trials in rheumatoid arthritis at four European centers.

SetPoint's microregulator is designed to supplement the body's natural Inflammatory Reflex by providing 'built-in' therapy at a lower cost and is intended to improve safety compared with drugs or biologic solutions.

  • Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis

    July 4, 2016 – Proceedings of the National Academy of Sciences of the United States of America - Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis.
    Read More
  • SetPoint Medical Presents Positive Clinical Results in Crohn’s Disease

    October 19, 2016 – SetPoint Medical, a biomedical technology company developing a bioelectronic therapy for inflammatory diseases, presented positive results from an ongoing study modulating the inflammatory reflex to treat Crohn’s Disease (CD), a debilitating disease caused by inflammation in the digestive tract. The data were presented at United European Gastroenterology Week (UEGW) in Vienna.
    Read More
  • The New York Times - Can the Nervous System Be Hacked?

    May 23, 2014 – One morning in May 1998, Kevin Tracey converted a room in his lab at the Feinstein Institute for Medical Research in Manhasset, N.Y., into a makeshift operating theater and then prepped his patient — a rat — for surgery. A neurosurgeon, and also Feinstein Institute’s president, Tracey had spent more than a decade searching for a link between nerves and the immune system. His work led him to hypothesize that stimulating the vagus nerve with electricity would alleviate harmful inflammation. "The vagus nerve is behind the artery where you feel your pulse," he told me recently, pressing his right index finger to his neck.
    Read More
  • Could an electronic implant switch off rheumatoid arthritis?

    September 22, 2016 – Gabriel Weston investigates an astonishing new medical approach – bioelectronic medicine – which uses electrical stimulation of the nerves to treat diseases of the immune system.
    Read More

Get To Know The Management

Anthony Arnold
Mike Faltys
Ralph Zitnik, MD
Allan Will

S5 Box




Fields marked with an asterisk (*) are required.